← Back to Screener
Fennec Pharmaceuticals Inc. Common Stock (FENC)
Price$9.88
Value ScoreD
Growth ScoreA
Momentum ScoreB
Favorite Metrics
Price vs S&P 500 (26W)10.73%
Price vs S&P 500 (4W)46.86%
VGM Score58.19
Market Capitalization$343.20M
All Metrics
P/CF (Annual)8.12x
Book Value / Share (Quarterly)$1.09
P/TBV (Annual)5.91x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)207.19%
Cash Flow / Share (Quarterly)$-0.17
Price vs S&P 500 (YTD)18.03%
Gross Margin (TTM)92.76%
Net Profit Margin (TTM)-12.63%
EPS (TTM)$-0.28
10-Day Avg Trading Volume0.39M
EPS Excl Extra (TTM)$-0.28
Revenue Growth (5Y)204.69%
EPS (Annual)$-0.34
ROI (Annual)-27.46%
Gross Margin (Annual)91.57%
Net Profit Margin (5Y Avg)-2458.16%
Cash / Share (Quarterly)$1.16
Revenue Growth QoQ (YoY)72.64%
ROA (Last FY)-13.81%
Revenue Growth TTM (YoY)33.76%
EBITD / Share (TTM)$-0.25
ROE (5Y Avg)-70.75%
Operating Margin (TTM)-11.81%
Cash Flow / Share (Annual)$-0.37
P/B Ratio9.11x
P/B Ratio (Quarterly)5.63x
Net Income / Employee (Annual)$-270,600
EV / Revenue (TTM)7.33x
Net Interest Coverage (TTM)-6.24x
ROA (TTM)-14.17%
EV / EBITDA (TTM)107.23x
EPS Incl Extra (Annual)$-0.34
Current Ratio (Annual)6.37x
Quick Ratio (Quarterly)6.42x
3-Month Avg Trading Volume0.21M
52-Week Price Return22.59%
EV / Free Cash Flow (Annual)7.99x
Revenue / Employee (TTM)$1,148,500
Tangible BV / Share (Quarterly)$1.39
P/S Ratio (Annual)7.69x
Asset Turnover (Annual)0.63x
52-Week High$10.45
Operating Margin (5Y Avg)-2412.74%
EPS Excl Extra (Annual)$-0.34
26-Week Price Return26.66%
Quick Ratio (Annual)5.87x
13-Week Price Return15.33%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)6.98x
Enterprise Value$303.02M
Revenue / Share Growth (5Y)193.28%
Asset Turnover (TTM)0.65x
Book Value / Share Growth (5Y)-6.51%
Revenue / Employee (Annual)$1,240,100
Inventory Turnover (Annual)2.87x
Pretax Margin (Annual)-21.58%
Cash / Share (Annual)$1.08
3-Month Return Std Dev98.34%
Net Income / Employee (TTM)$-232,700
ROE (Last FY)-27.46%
Net Interest Coverage (Annual)-6.24x
EPS Basic Excl Extra (Annual)$-0.34
Receivables Turnover (TTM)2.42x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-0.28
Receivables Turnover (Annual)2.47x
ROI (TTM)-12.54%
P/S Ratio (TTM)8.30x
Pretax Margin (5Y Avg)-2457.96%
Revenue / Share (Annual)$1.56
Tangible BV / Share (Annual)$7.48
Forward P/E17.67x
Price vs S&P 500 (52W)-5.61%
Year-to-Date Return28.96%
5-Day Price Return0.00%
EPS Normalized (Annual)$-0.34
ROA (5Y Avg)-47.99%
Net Profit Margin (Annual)-21.82%
Month-to-Date Return53.00%
Cash Flow / Share (TTM)$-0.53
EBITD / Share (Annual)$-0.29
Operating Margin (Annual)-18.60%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-65.46%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-0.28
P/TBV (Quarterly)15.62x
P/B Ratio (Annual)7.41x
Inventory Turnover (TTM)2.43x
Pretax Margin (TTM)-12.38%
Book Value / Share (Annual)$1.04
Price vs S&P 500 (13W)5.58%
Beta1.08x
P/FCF (Annual)12.72x
Revenue / Share (TTM)$1.16
ROE (TTM)-12.54%
52-Week Low$5.65
vGradeD
gGradeA
mGradeB
vgmGradeC
Show chart for
Earnings Surprise History
Q1 260.01est. -0.01
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
4.25
4.23
4.23
4.23
Industry Peers — Biological Products(178)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
FENCFennec Pharmaceuticals Inc. Common Stock | D | A | B | $9.88 |
| AMGNAmgen Inc | C | C | C | $329.13 |
| GILDGilead Sciences Inc | C | B | C | $131.10 |
| ARGXargenx SE American Depositary Shares | D | A | C | $836.09 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | A | $163.68 |
| BIIBBiogen Inc. Common Stock | B | D | B | $192.23 |
| BNTXBioNTech SE American Depositary Share | C | C | C | $91.70 |
| MRNAModerna, Inc. Common Stock | C | B | B | $46.06 |
| NBIXNeurocrine Biosciences Inc | C | B | B | $161.00 |
| EXELExelixis Inc | C | B | B | $50.28 |
| KRYSKrystal Biotech, Inc. Common Stock | D | B | B | $298.10 |
About
Fennec Pharmaceuticals is a biopharmaceutical company commercializing PEDMARK, a novel formulation designed to prevent cisplatin-induced hearing loss in children undergoing chemotherapy. The company addresses a significant side effect of cancer treatment with a first-in-class therapeutic approach. Operations are based in the United States.